Telesis bio stock.

Telesis Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 Nov. 13: CI Telesis Bio, Inc. Provides Earnings Guidance for 2023 Nov. 13: CI Telesis Bio, Inc. Announces Default of 2022 Term Loan Agreement Nov. 09Execute Telesis Bio Buy or Sell Advice ; Odds of Distress. Quite High ; Economic Sensitivity. Slowly supersedes the market ; Analyst Consensus. Buy ; Financial ...About Telesis Bio Telesis Bio Inc. is building biology. Creators of the BioXp® system, the world’s only fully automated gene synthesis platform, and the industry-standard Gibson Assembly® method, Telesis Bio Inc. is focused on enabling researchers with the tools they need to rapidly and securely design, code, and create synthetic DNA. Stock Performance. Shares of Telesis Bio were trading at $0.681 as of November 09. Over the last 52-week period, shares are down 61.71%. Given that these returns are generally negative, long-term ...

Past sector events for Telesis Bio, Inc. 2023-11-30 01:30 am Q2 2024 Earnings Release

SAN DIEGO, Calif., June 14, 2021 (GLOBE NEWSWIRE) — Telesis Bio, Inc. (“Telesis Bio”), creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, today announced the launch of its public offering of 6.7 million shares of its common stock. The initial public offering price is ...Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of ...

28 Jun 2023 ... The securities purchase agreement provides Telesis Bio with $28 million in initial upfront funding through the private placement of redeemable ...Quarterly Results.Telesis Bio, Inc. (TBIO) is a leader in automated multi-omic and synthetic biology solutions. The stock price, news, quote and history of the company are available on Yahoo Finance. See the latest performance outlook, earnings date, dividend yield, analyst report and more. Stock information. Stock Quote & Chart; Historic Price Lookup; Analyst Coverage; Corporate governance. Governance Overview; Board of Directors; Management; Committee Composition; Financials + filings. SEC Filings; Annual Reports & Proxies; Quarterly Results; IR resources. Investor FAQs; Email Alerts; Contact IR

Legal Name Telesis Bio Inc. Stock Symbol NASDAQ:TBIO. Company Type For Profit. Contact Email [email protected]. Phone Number +1 855-474-4362. Telesis Bio is a biotech company that empowers researchers with the tools to secure design, code, and create synthetic DNA and mRNA. Telesis Bio was founded in 2013 and was headquartered in San Diego, USA.

Telesis Bio, Inc. (NASDAQ:NASDAQ:TBIO) Q4 2022 Earnings Conference Call March 21, 2023 4:30 PM ETCompany ParticipantsJen Carroll - VP, IRTodd Nelson -...

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2023 financial results on Monday, November 13, 2023, after the market closes. The press release can be accessed via the Investor section of Telesis Bio ... Telesis Bio (NASDAQ:TBIO) said Wednesday it has signed an agreement with institutional investors to provide the company with funding of $28 million through a private placement of redeemable ...Telesis Bio is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Telesis Bio's performance made by these analysts are theirs alone …43838ea61452e19e1b5e1aaab481e4.3eSTyuTu1LpmAO0GiZIPXUIb4wo3mrsunUwo9oucciw.ipDf …Legal Name Telesis Bio Inc. Stock Symbol NASDAQ:TBIO. Company Type For Profit. Contact Email [email protected]. Phone Number +1 855-474-4362. Telesis Bio is a biotech company that empowers researchers with the tools to secure design, code, and create synthetic DNA and mRNA. Telesis Bio was founded in 2013 and was …

Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building …Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of ...See the latest Telesis Bio Inc stock price (TBIO:XNAS), related news, valuation, ... Telesis Bio Inc is a synthetic biology company focused on enabling researchers to rapidly, accurately, and ...Nov 28, 2023 · The average price recommended by analysts for Telesis Bio Inc (TBIO) is $4.00, which is $3.66 above the current market price. The public float for TBIO is 8.76M and currently, short sellers hold a 3.69% of that float. On November 28, 2023, TBIO’s average trading volume was 182.53K shares. The electric vehicle boom is accelerating – and fast. Get instant access to exclusive stock lists, expert market analysis and powerful tools with 2 months of IBD Digital for only $20! Get market updates, educational videos, webinars, and stock analysis. Learn how you can make more money with IBD's investing tools, top-performing stock lists, and educational content. SAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, and Cellibre, a leading manufacturing technology company, today announced initiation of work under a collaboration to optimize the development and validation of Telesis Bio’s BioXp ® Digital …

Telesis Bio. Daniel Gibson, Ph.D., CTO and Co-founder to Present “Building Biology Overnight: Eliminating Synthesis Bottlenecks with Hands-free Automated Synthetic Biology Solutions”. SAN ...

Discover historical prices for TBIO stock on Yahoo Finance. View daily, weekly or monthly format back to when Telesis Bio, Inc. stock was issued. SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, after the market closes. Read more. June 8, 2023.Telesis Bio Inc (TBIO) Stock Price & News - Google Finance Markets Dow Jones 34,337.87 +0.16% +54.77 S&P 500 4,411.55 -0.084% -3.69 13,767.74 -0.22% -30.36 Russell 1,705.50 +0.010% +0.18 VIX...Telesis Bio reflects that expansion and growth,” stated Dr. Nelson. The new name reflects the focus, strategic vision, and growth of the Company. There will be no change to corporate structure ...Telesis Bio Appoints William J. Kullback Chief Financial Officer. SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in …Telesis Bio Inc. stock performance at a glance Check Telesis Bio Inc.’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. TBIO Stock Performance

Telesis Bio's stock price has surged recently, but its but its P/S still remains modest. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market ...

Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building …

Nov 20, 2023 · The average price predicted for Telesis Bio Inc (TBIO) by analysts is $4.00, which is $3.63 above the current market price. The public float for TBIO is 8.76M, and at present, short sellers hold a 3.69% of that float. On November 20, 2023, the average trading volume of TBIO was 38.46K shares. SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter ...Novel name reflects expansion of capabilities and solutions. SAN DIEGO, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced a plan to change its Company name to Telesis Bio. “Our innovative and pioneering spirit, and the versatility …Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building …SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third ...SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leader in molecular biology automation solutions for multi-omic and synthetic biology applications, today announced ...Nov 18, 2023 · Telesis Bio Inc (NASDAQ:TBIO) showed a performance of -61.05% in past 30-days. Number of shares sold short was 0.32 million shares which calculate 14.15 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $4.00 to the stock, which implies a rise of 90.75% to its current value. 43838ea61452e19e1b5e1aaab481e4.3eSTyuTu1LpmAO0GiZIPXUIb4wo3mrsunUwo9oucciw.ipDf …

Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of ...TBIONasdaq Stock Market • delayed by 15 minutes • CURRENCY IN USD • Healthcare Equipment & Supplies. TELESIS BIO INC. (TBIO).Nov 30, 2023 · Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of ... Instagram:https://instagram. idev etfsp 500 stock listtic tok challengesxlu ticker Telesis Bio Inc does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Telesis Bio Inc’s trailing 12-month revenue is $31.1 million with a -128.1% profit margin. Year-over-year quarterly sales growth most recently was 52.6%. Analysts expect adjusted earnings to reach $-0.897 per share for the current fiscal ... best app to trade otc stockssunrun subsidiaries $0.38 -0.0199 [-4.98%] Last update: 4:58PM (Delayed 15-Minutes) Get Real Time Here $0.38 0 [0.00%] Profile News Analyst Ratings Guidance Dividends Earnings Insider … spy call options Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building of ...Telesis Bio Inc. is engaged in providing automated multi-omic and synthetic biology solutions. The Company's synthetic biology solution addresses the bottlenecks across the multi-step process of building deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA), as well as the limitations of solutions that prevent the building …The latest price target for . Telesis Bio (NASDAQ: TBIO) was reported by Keybanc on August 11, 2023.The analyst firm set a price target for $0.00 expecting TBIO to fall to within 12 months (a ...